Piperacillin/tazobactam is a new combination of a broad-spectrum penicillin and a beta-
lactamase inhibitor. In studies in healthy volunteers, the pharmacokinetics of piperacillin …

The safety of piperacillin/tazobactam was investigated in Phase I and Phase III clinical
studies. In 22 Phase I pharmacokinetic studies, 242 healthy subjects and 232 patients were …

Study Objective. To compare the pharmacokinetic and pharmacodynamic profiles of two
dosing regimens for piperacillin‐tazobactam against commonly encountered pathogens …

Synopsis Combining tazobactam, a β-lactamase inhibitor, with the ureidopenicillin,
piperacillin, successfully restores the activity of piperacillin against β-lactamase-producing …

Ten volunteers received piperacillin (4 g), piperacillin (4 g) plus tazobactam (0.5 g)(Tazocin),
and ticarcillin (3 g) plus clavulanic acid (0.2 g)(Timentin) intravenously over 30 min in a …

The pharmacokinetic properties of piperacillin/tazobactam are summarized. The data on
piperacillin show that the behaviour of this well established agent is the same when given in …

The pharmacokinetics and pharmacodynamics of two multiple-dose regimens of piperacillin-
tazobactam (3.375 g every 6 h and 4.5 g every 8 h) were evaluated at steady state for 12 …

Objective: To discuss the antimicrobial activity, pharmacokinetics, clinical efficacy, and
adverse effect profile of piperacillin/tazobactam, a new beta-lactam/beta-lactamase inhibitor …

The pharmacodynamics of dosage regimens of piperacillin alone or in combination with
tazobactam against piperacillin-resistant or-susceptible bacteria were studied in an in vitro …

Polymicrobial infections are characterized by the presence of micro-organisms from more
than one group of bacteria. Empirical treatment of polymicrobial infections requires an agent …